Struggling with sustainability? WildSight’s new AI-powered platform offers actionable solutions
As global environmental regulations tighten and corporate sustainability becomes a boardroom priority, businesses face increasing pressure to report on their nature-related impacts. Enter WildSight, an ... Read More
Gilead Sciences to acquire British biotech company MiroBio for $405m
Gilead Sciences has agreed to acquire MiroBio, a clinical-stage British biotech company, in an all-cash deal worth around $405 million in a move to gain ... Read More
India grants emergency approval to Covishield and Covaxin vaccines for Covid-19
In a significant development in the battle against Covid-19, the Drugs Controller General of India (DCGI) has granted emergency approval for two vaccines—Covishield, developed by ... Read More
India’s DCGI grants emergency approval to Covishield and Covaxin vaccines
In a major step forward in India’s fight against the Covid-19 pandemic, the Drugs Controller General of India (DCGI) has granted emergency use approval to ... Read More
Oxford University develops rapid diagnostic test for Covid-19 detection in five minutes
A team of scientists from Oxford University's Physics Department has unveiled a groundbreaking diagnostic test capable of detecting and identifying Covid-19 within just five minutes. ... Read More
COV001 clinical trial results : Oxford vaccine ChAdOx1 nCoV-19 triggers strong immune response
COV001 clinical trial results : AstraZeneca and Oxford University said that interim results from the phase 1/2 COV001 clinical trial showed the ChAdOx1 nCoV-19 vaccine ... Read More
ChAdOx1 nCoV-19 vaccine : Russia’s R-Pharm signs deal with AstraZeneca
Russian pharma company R-Pharm has reportedly signed an agreement with AstraZeneca for manufacturing the ChAdOx1 nCoV-19 vaccine being developed by the latter in collaboration with ... Read More
Oxford University ChAdOx1 nCoV-19 vaccine trial begins in humans
Researchers at the University of Oxford in the UK have commenced the ChAdOx1 nCoV-19 vaccine trial in healthy human volunteers to test the vaccine candidate's ... Read More
Evox Therapeutics secures £35.5m in Series B to advance exosome therapeutics
Evox Therapeutics, an innovative biotechnology company spun out from Oxford University, has successfully raised £35.5 million in a Series B financing round. The round was ... Read More